Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: Newsfilter
Management Changes: Calidi Biotherapeutics has strengthened its leadership team by appointing Eric Poma, PhD, as CEO and Guy Travis Clifton, MD, as Chief Medical Officer, both bringing extensive biopharmaceutical experience to the company.
Clinical Developments: The FDA has cleared Calidi's IND application for CLD-201, an innovative stem cell-based immunotherapy targeting solid tumors, while the company is advancing its Redtail platform with IL15-superagonist as a key payload for tumor treatment.
Analyst Views on CLDI
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
